Related Parties - Additional Information (Details) - USD ($) $ in Thousands |
3 Months Ended | ||||
|---|---|---|---|---|---|
Mar. 31, 2026 |
Mar. 31, 2025 |
Dec. 31, 2025 |
|||
| Related Parties | |||||
| Research and development | [1] | $ 60,819 | $ 46,387 | ||
| Paragon Therapeutics, Inc | Minimum | |||||
| Related Parties | |||||
| Percentage of capital stock beneficially owns | 5.00% | ||||
| Related party | Paragon Therapeutics, Inc | |||||
| Related Parties | |||||
| Due to related party | $ 600 | $ 2,100 | |||
| Research and development | $ 600 | ||||
| |||||
| X | ||||||||||
- Definition Percentage of capital stock beneficially owns. No definition available.
|
| X | ||||||||||
- Definition Amount of liabilities classified as other. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|